Treatment of facial atrophic scars with Esthélis, a hyaluronic acid filler with polydense cohesive matrix (CPM).
BACKGROUND
The treatment of atrophic scars is difficult and dermal filler materials provide a simple alternative with immediate results. Esthélis® is an injectable non-animal crosslinked hyaluronic acid of Swiss origin characterized by a polydense cohesive matrix (CPM®) which produces a gel of uniform consistency with better biointegration to the tissues and a longer duration.


OBJECTIVE
To evaluate Esthélis in the treatment of atrophic scars.


METHODS
Twelve patients aged 18-56 years with facial atrophic scars caused by acne vulgaris, dog bite, piercing, basal cell carcinoma and leishmaniasis were treated with Esthélis. The injection technique was linear threading, serial puncture or a combination of both. Clinical efficacy was assessed independently by the authors and by patients immediately, one week and one month after the injection. Adverse events were registered.


RESULTS
Authors described the results as moderate (27%), good (57%) and excellent (17%), immediately, one week and one month after the injection. Patients evaluated the cosmetic improvement as good (42%) or excellent (58%) one month after the treatment. Pain during the injection was described as slight or moderate. Only mild erythema was observed immediately after injection, which spontaneously resolved within few hours.


CONCLUSIONS
Esthélis showed good or excellent results in most patients with atrophic scars, and these were perceived as even better when patients evaluated the cosmetic improvement. The best results were observed in patients with more deforming scars such as surgical scars or trauma.
Department of Dermatology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. ariehn@gmail.com
Ariel
A
Hasson
William A
WA
Romero
D000152:Acne Vulgaris / Q000150:complications / Q000473:pathology; D000328:Adult; D001284:Atrophy; D002280:Basal Cell Carcinoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002722:Chlorobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D002921:Cicatrix / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D003357:Cosmetic Techniques / Q000009:adverse effects; D016503:Drug Delivery Systems; D005079:Excipients; D005145:Face; D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D007267:Injections; D008875:Middle Aged; D011677:Punctures; D013440:Sulfides / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D002722:Chlorobenzenes; D005079:Excipients; D013440:Sulfides; C037534:4-chlorophenyl methyl sulfide; D006820:Hyaluronic Acid